Search Results
14 protocol(s) meet the specified criteria
103123Open  
Multicenter, Phase I, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, Efficacy, and Pharmacokinetics in Patients with Advanced Malignancies

103706Open  
Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of ARQ 531 in Selected Subjects with Relapsed or Refractory Hematologic Malignancies

72013Open  
Feasibility and Outcomes of Allogeneic Hematopoietic Cell Transplantation (HCT) Compared to Conventional Chemotherapy for Older and Medically Infirm Patients Diagnosed with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes: A Prospective Observational Study

76134Open  
Prospective Evaluation of Ruxolitinib Efficacy for CNL/aCML Patients with Mutation of CS3FR

80837Open  
Multicenter Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Intermediate-2 and High-Risk Myelodysplastic Syndrome

84699Open  
Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults

85518Open  
Dose-Escalation Study of Selinexor (KPT-330), a Selective Inhibitor of Nuclear Export, and Ibrutinib, a Bruton Tyrosine Kinase Inhibitor, in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma

92047Open  
Randomized, Phase II Study of CX-01 Combined with Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia

94141Open  
Phase I, Multicenter, Open-Label Study of Oral ABL001 in Patients with Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

94441Open  
Phase IB Study Evaluating the Safety and Pharmacology of Atezolizumab (Anti-PD-L1 Antibody) Administered in Combination with Immunomodulatory Agents in Patients with Acute Myeloid Leukemia

97775Open  
Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients after Chemotherapy (Remain Trial)

97813Open  
Phase II Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination with Ruxolitinib in Subjects with Myelofibrosis

98319Open  
Randomized, Double-Blind, Placebo Controlled Study of Venetoclax in Combination with Azacitidine versus Azacitidine in Treatment Naïve Elderly Subjects with Acute Myeloid Leukemia who are Ineligible for Standard Induction Therapy

99707Open  
Phase I, Non-Randomized, Open-Label/Phase II Randomized, Blinded Study of ProTmune versus Non-Programmed Mobilized Peripheral Blood Cells for Allogeneic Hematopoietic Cell Transplantation in Adult Subjects with Hematologic Malignancies